About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 5812 record(s)
Req # A-2024-000017
Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number:…Organization: Health Canada
April 2024
Req # A-2024-000028
Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report…Organization: Health Canada
April 2024
Req # A-2024-000032
Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.Organization: Health Canada
April 2024
Req # A-2024-000068
Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.Organization: Health Canada
April 2024
Req # A-2023-00019
All final versions of documentation received or generated by the IAA related to the Nuclear Waste Management Organization's "Adaptive Phased Management" between November 15, 2022 and September 31st, 2023Organization: Impact Assessment Agency of Canada
April 2024
Req # A-2023-00031
Documents related to discussions of project designation with the Pathways Alliance. Limit Jan. 1, 2023 to Dec. 1, 2023. Exclude drafts.Organization: Impact Assessment Agency of Canada
April 2024
Req # A-2023-00038
Tout documents relatifs à la compagnie 6729274 CANADA INC. (la « Société »)Organization: Impact Assessment Agency of Canada
April 2024
Req # A-2023-00039
Tout documents relatifs à la compagnie Acier d'armature Ferneuf IncOrganization: Impact Assessment Agency of Canada
April 2024
Nothing to report this month
Organization: Thunder Bay Port Authority
Req # A-2016-000420
Documents relating to Health Canada’s approval of INFLECTRA (Drug Identification Number (DIN) # 02419475): All Health Canada reviewers reports and reviewer comments; and all minutes from any pre-Supplement to a New Drug Submission (SNDS) meetings…Organization: Health Canada
March 2024